JP2014521687A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521687A5
JP2014521687A5 JP2014523996A JP2014523996A JP2014521687A5 JP 2014521687 A5 JP2014521687 A5 JP 2014521687A5 JP 2014523996 A JP2014523996 A JP 2014523996A JP 2014523996 A JP2014523996 A JP 2014523996A JP 2014521687 A5 JP2014521687 A5 JP 2014521687A5
Authority
JP
Japan
Prior art keywords
infection
composition
protein
synthetic nanocarriers
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014523996A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521687A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/048670 external-priority patent/WO2013019669A2/en
Publication of JP2014521687A publication Critical patent/JP2014521687A/ja
Publication of JP2014521687A5 publication Critical patent/JP2014521687A5/ja
Pending legal-status Critical Current

Links

JP2014523996A 2011-07-29 2012-07-27 体液性および細胞傷害性tリンパ球(ctl)免疫応答を生成する合成ナノキャリア Pending JP2014521687A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161513526P 2011-07-29 2011-07-29
US201161513496P 2011-07-29 2011-07-29
US201161513527P 2011-07-29 2011-07-29
US61/513,526 2011-07-29
US61/513,527 2011-07-29
US61/513,496 2011-07-29
PCT/US2012/048670 WO2013019669A2 (en) 2011-07-29 2012-07-27 Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017158401A Division JP2018030837A (ja) 2011-07-29 2017-08-21 体液性および細胞傷害性tリンパ球(ctl)免疫応答を生成する合成ナノキャリア

Publications (2)

Publication Number Publication Date
JP2014521687A JP2014521687A (ja) 2014-08-28
JP2014521687A5 true JP2014521687A5 (enExample) 2015-09-10

Family

ID=47597380

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014523996A Pending JP2014521687A (ja) 2011-07-29 2012-07-27 体液性および細胞傷害性tリンパ球(ctl)免疫応答を生成する合成ナノキャリア
JP2017158401A Pending JP2018030837A (ja) 2011-07-29 2017-08-21 体液性および細胞傷害性tリンパ球(ctl)免疫応答を生成する合成ナノキャリア

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017158401A Pending JP2018030837A (ja) 2011-07-29 2017-08-21 体液性および細胞傷害性tリンパ球(ctl)免疫応答を生成する合成ナノキャリア

Country Status (12)

Country Link
US (3) US20130028857A1 (enExample)
EP (1) EP2736537A4 (enExample)
JP (2) JP2014521687A (enExample)
KR (1) KR20140050698A (enExample)
CN (3) CN109172819A (enExample)
AU (3) AU2012290306B2 (enExample)
BR (1) BR112014002139A2 (enExample)
CA (1) CA2843274A1 (enExample)
EA (1) EA201490381A1 (enExample)
IL (2) IL230269B (enExample)
MX (1) MX2014001142A (enExample)
WO (3) WO2013019669A2 (enExample)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012524780A (ja) * 2009-04-21 2012-10-18 セレクタ バイオサイエンシーズ インコーポレーテッド Th1バイアス応答をもたらす免疫ナノ治療薬(Immunonanotherapeutics)
CN107252482A (zh) 2009-05-27 2017-10-17 西莱克塔生物科技公司 具有不同释放速率的纳米载体加工组分
CA2771863A1 (en) * 2009-08-26 2011-03-17 Selecta Biosciences, Inc. Compositions that induce t cell help
WO2011150258A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
EP2637697A4 (en) 2010-11-12 2016-07-13 Cour Pharmaceuticals Dev Company MODIFIED IMMUNOMODULATING PARTICLES
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9987354B2 (en) 2011-04-29 2018-06-05 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells
US20130028857A1 (en) 2011-07-29 2013-01-31 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドModernaTX,Inc. 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
HK1206612A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
KR102283760B1 (ko) 2012-06-21 2021-08-03 노쓰웨스턴유니버시티 펩티드 접합된 입자
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
CA3261641A1 (en) 2013-03-13 2025-06-12 Oncour Pharma, Inc. Immune-modifying particles for the treatment of inflammation
WO2014145749A1 (en) * 2013-03-15 2014-09-18 The Brigham And Women's Hospital, Inc. Targeted polymeric inflammation-resolving nanoparticles
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CN110251675A (zh) 2013-05-03 2019-09-20 西莱克塔生物科技公司 降低或预防响应于非变应原性抗原的过敏反应的致耐受性合成纳米载体
WO2014179771A1 (en) * 2013-05-03 2014-11-06 Selecta Biosciences, Inc. Dosing combinations for reducing undesired humoral immune responses
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
RS59801B2 (sr) 2013-08-13 2024-03-29 Univ Northwestern Čestice konjugovane peptidom
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
KR102507624B1 (ko) 2013-11-22 2023-03-09 미나 테라퓨틱스 리미티드 C/ebp 알파 짧은 활성화 rna 조성물 및 사용 방법
JP6527516B2 (ja) 2013-12-03 2019-06-05 ノースウェスタン ユニバーシティ リポソーム粒子、前述のものを作製する方法及びその使用
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US20150359865A1 (en) * 2014-06-17 2015-12-17 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease
CA2953273C (en) 2014-07-09 2022-07-26 Unilever Plc Alkaline laundry liquid composition comprising polyesters
EP2966160A1 (en) 2014-07-09 2016-01-13 Clariant International Ltd. Storage-stable compositions comprising soil release polymers
WO2016010788A1 (en) 2014-07-15 2016-01-21 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Polyketal particles including a cpg oligodeoxynucleotide for the treatment of lung cancer
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
CA2958090A1 (en) * 2014-08-13 2016-02-18 The Regents Of The University Of California Biodegradable trehalose glycopolymers
WO2016037161A2 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
KR101892689B1 (ko) * 2014-10-14 2018-08-28 삼성전기주식회사 칩 전자부품 및 칩 전자부품의 실장 기판
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US20170025028A1 (en) * 2015-07-23 2017-01-26 Rhythmalytics LLC Actigraphy based biological rhythm modification methods and systems that result in a greater efficacy of applied medical treatment to a patient
MA47016A (fr) 2015-10-22 2018-08-29 Modernatx Inc Vaccins contre les virus respiratoires
US11433136B2 (en) 2015-12-18 2022-09-06 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
LT3394093T (lt) 2015-12-23 2022-04-25 Modernatx, Inc. Ox40 ligandus koduojančių polinukleotidų naudojimo būdai
EP3400023A1 (en) 2016-01-10 2018-11-14 ModernaTX, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
US20190184013A1 (en) * 2016-05-23 2019-06-20 University Of Miami Compositions for selective humoral responses and methods of use thereof
CN106065047B (zh) * 2016-07-14 2019-02-26 山东省肿瘤防治研究院 一种肝靶向阳离子聚合物及其制备方法与应用
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
JP2020501545A (ja) 2016-12-08 2020-01-23 キュアバック アーゲー 肝疾患の処置または予防のためのrna
ES3036482T3 (en) 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
US12121573B2 (en) 2019-07-14 2024-10-22 Tianxin Wang Methods and agents including STING agonist to treat tumor
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
CA3068012A1 (en) 2017-06-23 2018-12-27 Pathovax Llc Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
KR20200028997A (ko) 2017-07-13 2020-03-17 노오쓰웨스턴 유니버시티 올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
EP4183882A1 (en) 2017-09-08 2023-05-24 MiNA Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
EP4219715A3 (en) 2017-09-08 2023-09-06 MiNA Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
SG11202002044WA (en) 2017-09-21 2020-04-29 Emergex Vaccines Holding Ltd MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus
US11566246B2 (en) 2018-04-12 2023-01-31 Mina Therapeutics Limited SIRT1-saRNA compositions and methods of use
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
CA3125184A1 (en) 2018-12-27 2020-07-02 Verimmune Inc. Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
WO2020208361A1 (en) 2019-04-12 2020-10-15 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
AU2020287627A1 (en) 2019-06-04 2021-11-18 Selecta Biosciences, Inc. Formulations and doses of PEGylated uricase
CN112111042B (zh) * 2019-06-21 2024-04-05 康码(上海)生物科技有限公司 一种生物磁性微球及其制备方法和使用方法
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
CN110938200B (zh) * 2019-12-05 2021-04-20 大连理工大学 一种侧链含二甲基吡啶胺类聚酯的制备方法
MX2019015508A (es) 2019-12-18 2021-06-21 Univ Guadalajara Nanopartículas para el tratamiento del cáncer.
CN111122429B (zh) * 2019-12-31 2022-04-22 华南理工大学 纳米纤维素纤化程度的快速检测方法
US20220193225A1 (en) * 2020-08-31 2022-06-23 Bruce Lyday Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins
CN114177282B (zh) * 2020-09-14 2024-03-15 苏州大学 氟化聚乙烯亚胺在制备疫苗或预防/治疗病毒/细菌引起的疾病的制剂中的应用
US11858964B2 (en) 2020-10-19 2024-01-02 Verimmune Inc. Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
JP2024511092A (ja) 2021-03-26 2024-03-12 ミナ セラピューティクス リミテッド TMEM173saRNA組成物及び使用方法
US20240342206A1 (en) 2021-07-30 2024-10-17 CureVac SE mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
WO2023144193A1 (en) 2022-01-25 2023-08-03 CureVac SE Mrnas for treatment of hereditary tyrosinemia type i
EP4482962A1 (en) 2022-02-24 2025-01-01 IO Biotech ApS Nucleotide delivery of cancer therapy
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
TW202440929A (zh) 2022-12-14 2024-10-16 加拿大商普羅維登斯治療控股公司 用於感染性疾病的組合物和方法
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
EP4520345A1 (en) 2023-09-06 2025-03-12 Myneo Nv Product
WO2025188694A1 (en) 2024-03-05 2025-09-12 Bristol-Myers Squibb Company Tricyclic tlr7 agonists and uses thereof
US20250282776A1 (en) 2024-03-05 2025-09-11 Bristol-Myers Squibb Company Bicyclic TLR7 Agonists and Uses Thereof
WO2026027887A2 (en) 2024-08-02 2026-02-05 Mina Therapeutics Limited Hbg1/2-sarna compositions and methods of use

Family Cites Families (332)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7461M (enExample) 1968-06-19 1970-01-05
GB1355961A (en) 1970-02-27 1974-06-12 Wellcome Found Preparation of immunosuppressive antilymphocytic serum
CH594444A5 (enExample) 1972-12-04 1978-01-13 Gerd Birrenbach
DK143689C (da) 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4756907A (en) 1978-10-17 1988-07-12 Stolle Research & Development Corp. Active/passive immunization of the internal female reproductive organs
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
JPS63122620A (ja) 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5804178A (en) 1986-11-20 1998-09-08 Massachusetts Institute Of Technology Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
FR2608988B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
US5912017A (en) 1987-05-01 1999-06-15 Massachusetts Institute Of Technology Multiwall polymeric microspheres
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5114703A (en) 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
GB9016885D0 (en) 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DK0531497T3 (da) 1991-04-02 1998-03-23 Biotech Australia Pty Ltd Orale indgivelsessystemer til mikropartikler
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
WO1994002068A1 (en) 1992-07-21 1994-02-03 The General Hospital Corporation System of drug delivery to the lymphatic tissues
GB9216082D0 (en) 1992-07-28 1992-09-09 Univ Nottingham Lymphatic delivery composition
US6608201B2 (en) 1992-08-28 2003-08-19 3M Innovative Properties Company Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
AU4932493A (en) 1992-09-25 1994-04-26 Dynagen, Inc. An immunobooster for delayed release of immunogen
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
JPH08505625A (ja) 1993-01-11 1996-06-18 ダナ−ファーバー キャンサー インスティチュート 細胞毒性tリンパ球応答の誘導
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
WO1994018955A1 (en) 1993-02-22 1994-09-01 Alza Corporation Compositions for oral delivery of active agents
EP0689430B1 (de) 1993-03-17 1997-08-13 Silica Gel Ges.M.B.H Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben
WO1995003035A1 (en) 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
PT735893E (pt) 1993-09-14 2009-03-06 Pharmexa Inc Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
DE69529054T2 (de) 1994-02-28 2003-08-21 Nanopharm Ag System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
CA2207961A1 (en) 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same
US5876727A (en) 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US5866132A (en) 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
WO1997004747A1 (en) 1995-07-27 1997-02-13 Dunn James M Drug delivery systems for macromolecular drugs
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
US6946133B1 (en) 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
DE69723434T2 (de) 1996-04-26 2004-05-19 Rijksuniversiteit Te Leiden Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US6043224A (en) 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
ES2290969T3 (es) 1996-10-25 2008-02-16 Minnesota Mining And Manufacturing Company Compuestos modificadores de la respuesta inmune para el tratamiento de enfermedades mediadas por th2 y relacionadas.
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6211159B1 (en) 1997-04-11 2001-04-03 University Of Toronto Flagellin gene, FlaC of campylobacter
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
WO1998052581A1 (en) 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
ATE423789T1 (de) 1997-09-16 2009-03-15 Univ Oregon Health & Science Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t- zellen
DE19745950A1 (de) 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
US6329381B1 (en) 1997-11-28 2001-12-11 Sumitomo Pharmaceuticals Company, Limited Heterocyclic compounds
US6254890B1 (en) 1997-12-12 2001-07-03 Massachusetts Institute Of Technology Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
US6197229B1 (en) 1997-12-12 2001-03-06 Massachusetts Institute Of Technology Method for high supercoiled DNA content microspheres
FR2775435B1 (fr) 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
JP2002510644A (ja) 1998-04-03 2002-04-09 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
EP1077708A1 (en) 1998-05-06 2001-02-28 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
SE9801923D0 (sv) 1998-05-29 1998-05-29 Independent Pharmaceutical Ab Nicotine vaccine
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
DE69930642T2 (de) 1998-07-29 2006-12-28 Chiron Corp., Emeryville Mikropartikel mit adsorbenten oberflächen, verfahren zu ihrer herstellung und ihrer verwendung
DE19839214C1 (de) 1998-08-28 2000-05-25 Aventis Res & Tech Gmbh & Co Verfahren zur Herstellung von sphärischen Mikropartikeln mit glatter Oberfläche, die ganz oder teilweise aus mindestens einem wasserunlöslichen linearen Polysaccharid bestehen, sowie mit diesem Verfahren erhältliche Mikropartikel und deren Verwendung
US6306640B1 (en) 1998-10-05 2001-10-23 Genzyme Corporation Melanoma antigenic peptides
KR100731820B1 (ko) 1998-10-05 2007-06-25 파멕사 에이/에스 치료적 백신화를 위한 새로운 방법
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
DK1126826T6 (en) 1998-11-02 2019-06-24 Alkermes Pharma Ireland Ltd Multiparticulate modified release of methylphenidate
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
WO2000032626A1 (en) 1998-11-25 2000-06-08 Regents Of The University Of Minnesota Methods of using epitope peptides of human pathogens
CN1193791C (zh) 1998-11-30 2005-03-23 希托斯生物技术股份公司 抗原的有序分子呈递,制备及使用的方法
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US6245776B1 (en) 1999-01-08 2001-06-12 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6444192B1 (en) 1999-02-05 2002-09-03 The Regents Of The University Of California Diagnostic imaging of lymph structures
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
ES2228454T3 (es) 1999-02-26 2005-04-16 Chiron S.R.L. Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg.
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
IL146106A0 (en) 1999-05-06 2002-07-25 Genetics Inst Use of soluble costimulatory molecules to enhance immune responses
US6800296B1 (en) 1999-05-19 2004-10-05 Massachusetts Institute Of Technology Modification of surfaces using biological recognition events
US6815170B1 (en) 1999-06-30 2004-11-09 John Wayne Cancer Institute Methods for lymph node identification
WO2001012071A1 (en) 1999-08-13 2001-02-22 Point Biomedical Corporation Microparticles useful as ultrasonic contrast agents and for lymphatic system
TR200200797T2 (tr) 1999-09-25 2002-10-21 University Of Iowa Research Foundation İmmünostimülatör nükleik asitler
CA2391534A1 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1294930B1 (en) 2000-01-13 2011-03-30 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US20050020525A1 (en) 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CN1406140A (zh) 2000-02-28 2003-03-26 吉倪塞思公司 纳米胶囊包封系统与方法
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
SE0000933D0 (sv) 2000-03-21 2000-03-21 Independent Pharmaceutica Ab Method of producing 6-substituted (S)-nicotine derivatives and intermediate compounds
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US7192725B2 (en) 2000-05-19 2007-03-20 University Of Toronto Flagellin gene, flaC of Campylobacter
US6610713B2 (en) 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
CA2319928A1 (en) 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
AU2001297913A1 (en) 2000-10-13 2002-12-23 Ligocyte Pharmaceuticals, Inc. Polyvalent nanoparticles
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
BR0114786A (pt) 2000-10-18 2003-08-12 Glaxosmithkline Biolog Sa Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
EP1355965B1 (en) 2000-10-19 2012-09-19 Ecole Polytechnique Fédérale de Lausanne (EPFL) Method of synthesizing block copolymers for multifunctional self-assembled systems
US7592008B2 (en) 2000-11-20 2009-09-22 The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois Membrane scaffold proteins
AU2006216669A1 (en) 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
AU2002231336B2 (en) 2000-12-27 2007-06-28 Surefire Medical, Inc. D/B/A Trisalus Life Sciences Immunomodulatory polynucleotides and methods of using the same
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7097837B2 (en) 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
EP2545937A1 (en) 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
EP1417236A4 (en) 2001-07-10 2010-03-17 Corixa Corp COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ENCAPSULATED PROTEINS AND ADJUVANTS IN MICROSPHERES
WO2003014316A2 (en) 2001-08-07 2003-02-20 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
US6818732B2 (en) 2001-08-30 2004-11-16 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
KR20050044314A (ko) 2001-11-07 2005-05-12 사이토스 바이오테크놀로지 아게 뼈 질환 치료용 항원 어레이
ES2320638T3 (es) 2001-11-07 2009-05-27 Cytos Biotechnology Ag Disposicion ordenada de antigenos il-5, il-13 o eotasina, para el tratamiento de enfermedades alergicas con un componente eosinofilico.
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
WO2003070909A2 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
AU2003230806B2 (en) 2002-04-04 2009-05-07 Zoetis Belgium S.A. Immunostimulatory G,U-containing oligoribonucleotides
US20040038303A1 (en) 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
US20080233181A1 (en) 2002-04-12 2008-09-25 Nagy Jon O Nanoparticle adjuvants for sub-unit vaccines
ATE394674T1 (de) 2002-04-22 2008-05-15 Univ Florida Funktionalisierte nanopartikel und verwendungsverfahren
AU2003276131A1 (en) 2002-06-18 2003-12-31 Epigenesis Pharmaceuticals, Inc. A dry powder oligonucleotide formulation, preparation and its uses
WO2004005325A2 (en) 2002-07-10 2004-01-15 The Ohio State University Research Foundation Antigen-polymer compositions
AU2003246690B2 (en) 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
EP1524994B1 (en) 2002-07-19 2011-04-27 Cytos Biotechnology AG Vaccine compositions containing amyloid beta1-6 antigen arrays
ATE488246T1 (de) 2002-08-15 2010-12-15 3M Innovative Properties Co Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort
US7488792B2 (en) 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
AU2003258714A1 (en) 2002-09-06 2004-03-29 Cytos Biotechnology Ag Immune modulatory compounds and methods
AU2003302226A1 (en) 2002-09-24 2004-06-30 University Of Kentucky Research Foundation Nanoparticle-based vaccine delivery system containing adjuvant
US7008411B1 (en) 2002-09-30 2006-03-07 Advanced Cardiovascular Systems, Inc. Method and apparatus for treating vulnerable plaque
NO20024755D0 (no) 2002-10-03 2002-10-03 Amersham Health As Metode
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
SE0203687D0 (sv) 2002-12-13 2002-12-13 Ian Harwigsson Med Adagit Fa Pharmaceutical Porous Particles
ES2381309T3 (es) 2002-12-23 2012-05-25 Dynavax Technologies Corporation Secuencia de oligonucleótidos inmunoestimuladores y métodos para usar los mismos
JP2006512391A (ja) 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー 組み合わせ免疫賦活薬
AU2004204942A1 (en) 2003-01-08 2004-07-29 Xencor, Inc Novel proteins with altered immunogenicity
US20040156846A1 (en) 2003-02-06 2004-08-12 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles using L6 antibodies
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Irm化合物およびトル様受容体8に関する方法および組成物
US8575110B2 (en) 2003-02-17 2013-11-05 Alpha-O Peptides G Peptidic nanoparticles as drug delivery and antigen display systems
US20040191215A1 (en) 2003-03-25 2004-09-30 Michael Froix Compositions for induction of a therapeutic response
JP5022028B2 (ja) 2003-03-26 2012-09-12 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト メラン−aペプチドアナログ−ウイルス様粒子コンジュゲート
WO2004084871A1 (en) 2003-03-26 2004-10-07 Ltt Bio-Pharma Co., Ltd. Intravenous nanoparticles for targenting drug delivery and sustained drug release
WO2004108072A2 (en) 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US7149574B2 (en) 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system
WO2005014110A1 (en) 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
US20050042298A1 (en) 2003-08-20 2005-02-24 Pardridge William M. Immunonanoparticles
JP5097400B2 (ja) 2003-09-03 2012-12-12 デンドリセラピューティクス、インク. 複合ワクチン
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
US20080160089A1 (en) 2003-10-14 2008-07-03 Medivas, Llc Vaccine delivery compositions and methods of use
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
CA2558916C (en) 2003-10-20 2009-09-22 William Marsh Rice University Method to fabricate microcapsules from polymers and charged nanoparticles
SG122973A1 (en) 2003-10-30 2006-06-29 Coley Pharm Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
JP2007512355A (ja) 2003-11-21 2007-05-17 アルザ コーポレイション 開裂性のpegで表面修飾されたリポソーム−dna複合体で媒介される遺伝子送達
US20070116768A1 (en) 2003-12-09 2007-05-24 Michael Chorny Sustained release preparations composed of biocompatible complex microparticles
EP3242318A1 (en) 2003-12-19 2017-11-08 The University of North Carolina at Chapel Hill Monodisperse micro-structure or nano-structure product
US20050191294A1 (en) 2003-12-31 2005-09-01 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy
US20070087986A1 (en) 2004-01-26 2007-04-19 Brett Premack Compositions and methods for enhancing immunity by chemoattractant adjuvants
US20050256073A1 (en) 2004-02-19 2005-11-17 Coley Pharmaceutical Group, Inc. Immunostimulatory viral RNA oligonucleotides
AU2005244260B2 (en) 2004-04-09 2010-08-05 3M Innovative Properties Company Methods, compositions, and preparations for delivery of immune response modifiers
ES2246695B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
WO2005108425A1 (en) 2004-05-10 2005-11-17 Cytos Biotechnology Ag Il-23 p19 antigen array and uses thereof
AU2005250170A1 (en) 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
KR101215808B1 (ko) 2004-06-11 2012-12-26 도꾸리쯔교세이호징 리가가쿠 겐큐소 조절성 세포 리간드를 리포좀에 함유시켜 이루어지는 의약
EP1768692B8 (en) 2004-07-01 2015-06-17 Yale University Targeted and high density drug loaded polymeric materials
WO2006014579A2 (en) 2004-07-08 2006-02-09 The Regents Of California Enhancing class i antigen presentation with synthetic sequences
US8017151B2 (en) 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
EP1797091A2 (en) 2004-09-14 2007-06-20 Novartis Vaccines and Diagnostics, Inc. Imidazoquinoline compounds
CN1692943A (zh) 2004-09-17 2005-11-09 四川大学 CpG DNA分子抗感染免疫制剂的制备和应用
JP5117191B2 (ja) 2004-10-01 2013-01-09 ミダテック リミテッド 抗原及びアジュバントを含むナノ粒子、並びに免疫原性構造
JP2008515915A (ja) 2004-10-07 2008-05-15 エモリー ユニバーシティー 多機能性ナノ粒子結合体およびそれらの使用
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
WO2006045796A2 (en) 2004-10-25 2006-05-04 Cytos Biotechnology Ag Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
WO2006045849A1 (en) 2004-10-29 2006-05-04 Cytos Biotechnology Ag T-cadherin antigen arrays and uses thereof
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
JP2008519052A (ja) 2004-11-05 2008-06-05 ザ ジェネラル ホスピタル コーポレイション 薬剤によるヒト遊走性細胞の合目的的挙動
ES2434029T3 (es) 2004-11-15 2013-12-13 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunogénicas que contiene antígeno de antrax, micropartículas de polímero biodegradable, y adyuvante inmunológico que contiene polinucleótido
US20060111271A1 (en) 2004-11-24 2006-05-25 Cerny Erich H Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements
US20070292386A9 (en) 2004-12-02 2007-12-20 Campbell Robert L Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
KR20070089186A (ko) 2004-12-13 2007-08-30 사이토스 바이오테크놀로지 아게 Il-15 항원 어레이 및 그 용도
ATE544774T1 (de) 2004-12-14 2012-02-15 Alnylam Pharmaceuticals Inc Rnai-modulation von mll-af4 und verwendungen dafür
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
CN101189339A (zh) 2005-03-22 2008-05-28 美得思达健康有限公司 诊断和治疗心血管疾病的递送系统和方法
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20080305161A1 (en) 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
US20060241076A1 (en) 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
KR101418367B1 (ko) 2005-05-04 2014-07-25 녹손 파르마 아게 에이치엠지에이-결합 핵산
AU2006243960A1 (en) 2005-05-10 2006-11-16 Emory University Strategies for delivery of active agents using micelles and particles
US9290617B2 (en) 2005-07-06 2016-03-22 Molly S. Shoichet Method of biomolecule immobilization on polymers using click-type chemistry
CA2618807C (en) 2005-08-12 2015-01-06 University Health Network Methods and devices for lymphatic targeting
WO2007028341A1 (fr) 2005-09-09 2007-03-15 Beijing Diacrid Medical Technology Co., Ltd. Nanomicelles servant de medicaments anticancereux a polyethylene phospholipides glycolyles contenant des vinca alcaloides
US7662949B2 (en) 2005-11-25 2010-02-16 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
ES2564241T3 (es) 2005-12-02 2016-03-21 Glaxosmithkline Biologicals Sa Nanopartículas para su uso en composiciones inmunogénicas
US20070184068A1 (en) 2005-12-14 2007-08-09 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
JP2009525341A (ja) 2006-01-31 2009-07-09 メディバス エルエルシー ワクチン送達組成物および使用法
US8021689B2 (en) 2006-02-21 2011-09-20 Ecole Polytechnique Federale de Lausanne (“EPFL”) Nanoparticles for immunotherapy
EP1991204A2 (en) 2006-02-24 2008-11-19 Novartis AG Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
EP2010530A2 (en) 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
EP2007435B1 (en) 2006-03-31 2019-12-18 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
WO2007118653A2 (de) 2006-04-11 2007-10-25 Koko Kosmetikvertrieb Gmbh & Co. Kg Nanopartikel, enthaltend nicotin und/oder cotinin, dispersionen und die verwendung derselben
CA2652280C (en) 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
US20110052697A1 (en) 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
CN101466720B (zh) 2006-06-12 2013-01-02 赛托斯生物技术公司 向rna噬菌体的病毒样颗粒内包装寡核苷酸的方法
WO2008054892A2 (en) 2006-06-16 2008-05-08 Florida Atlantic University Chitin micro-particles as an adjuvant
US20100028381A1 (en) 2006-06-19 2010-02-04 3M Innovative Properties Company Formulation for delivery of immune response modifiers
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008019142A2 (en) 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US20080171059A1 (en) 2006-08-07 2008-07-17 Shanshan Wu Howland Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens
CL2007002336A1 (es) 2006-08-11 2008-02-08 M S Panacea Biotec Ltd Composicion que tiene particulas que comprende elementos inorganicos, uno o mas ingredientes activos y opcionalmente, agentes moduladores de la tasa de liberacion; procedimiento para prepararla; las particulas, util para la entrega de ingredientes ac
WO2008033432A2 (en) 2006-09-12 2008-03-20 Coley Pharmaceutical Group, Inc. Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
EP2083857A4 (en) 2006-09-22 2010-03-24 Dana Farber Cancer Res Inc METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
EP3590503A1 (en) 2006-10-12 2020-01-08 The University of Queensland Compositions and methods for modulating immune responses
US20100303723A1 (en) 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
AU2007333225B2 (en) 2006-12-08 2014-06-12 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
WO2008071774A1 (en) 2006-12-14 2008-06-19 Cytos Biotechnology Ag Purification process for coat protein of rna bacteriophages
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
PL2115140T3 (pl) 2007-01-31 2017-03-31 Yu Dodatnio naładowane rozpuszczalne w wodzie proleki 1H-imidazo[4,5-c]chinolino-4-amin i powiązane związki o bardzo wysokich wskaźnikach penetracji przez skórę
ES2552471T3 (es) 2007-02-07 2015-11-30 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
US8889117B2 (en) 2007-02-15 2014-11-18 Yale University Modular nanoparticles for adaptable vaccines
US8354110B2 (en) 2007-03-07 2013-01-15 Uti Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
WO2008118861A2 (en) 2007-03-23 2008-10-02 The University Of North Carolina At Chapel Hill Discrete size and shape specific organic nanoparticles designed to elicit an immune response
ES2542058T3 (es) 2007-03-30 2015-07-30 Particle Sciences, Inc. Formulaciones en forma de partículas y usos de las mismas
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ(アミノ酸)ターゲッティング部分
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
CA2683063A1 (en) 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
AU2008239795A1 (en) 2007-04-12 2008-10-23 Emory University Novel strategies for delivery of active agents using micelles and particles
EP1982729A1 (en) 2007-04-20 2008-10-22 Cytos Biotechnology AG Vaccination Regimen for B-Cell Vaccines
EP2468763B1 (en) 2007-05-31 2014-06-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
WO2008157419A2 (en) 2007-06-13 2008-12-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic peptides of influenza virus
DK2083856T3 (da) 2007-08-15 2011-01-24 Circassia Ltd Peptider til desensibilisering mod allergener
US8394914B2 (en) 2007-08-24 2013-03-12 Board Of Trustees Of Michigan State University Functional polyglycolide nanoparticles derived from unimolecular micelles
EP3424525A1 (en) * 2007-10-12 2019-01-09 Massachusetts Institute Of Technology Vaccine nanotechnology
EP2244695A1 (en) 2007-12-07 2010-11-03 Novartis AG Compositions for inducing immune responses
CA2713879C (en) 2008-02-01 2020-01-07 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
KR101617790B1 (ko) 2008-02-26 2016-05-03 아파르나 바이오사이언시스 치료, 진단과 실험적 혼합물들의 운반을 위한 공학적으로 가변된 나노입자 및 치료용 관련 조성물
EP2250189A4 (en) 2008-02-26 2012-07-04 Univ California GYLCOPEPTIDES AND METHOD FOR THEIR PREPARATION AND USE
WO2009106999A2 (en) 2008-02-28 2009-09-03 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Hollow nanoparticles and uses thereof
US20110151015A1 (en) 2008-03-04 2011-06-23 Liquikia Technologies, Inc. Immunomodulator particles and methods of treating
US20090297621A1 (en) 2008-06-03 2009-12-03 Abbott Cardiovascular Systems Inc. Microparticles For The Treatment Of Disease
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
ES2765240T3 (es) 2008-06-16 2020-06-08 Pfizer Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas
EP2303236A4 (en) * 2008-07-01 2012-09-26 Univ Emory SYNERGISTIC INDUCTION OF HUMOR AND CELLULAR IMMUNITY BY COMBINATORY ACTIVATION OF TOLL-LIKE RECEPTORS
EP2328614A1 (en) 2008-08-06 2011-06-08 Novartis AG Microparticles for use in immunogenic compositions
WO2010018132A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Compounds
EA201100114A1 (ru) 2008-08-11 2011-10-31 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Производные пурина для применения в лечении аллергических, воспалительных и инфекционных заболеваний
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
WO2010018130A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
US20120034156A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
WO2010018384A1 (en) 2008-08-15 2010-02-18 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
WO2010039861A2 (en) 2008-09-30 2010-04-08 The Regents Of The University Of Michigan Dendrimer conjugates
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US20120015899A1 (en) 2008-10-25 2012-01-19 Plant Bioscience, Limited Modified plant virus particles and uses therefor
US9764012B2 (en) 2009-04-01 2017-09-19 University Of Miami Vaccine compositions and methods of use thereof
JP2012524780A (ja) 2009-04-21 2012-10-18 セレクタ バイオサイエンシーズ インコーポレーテッド Th1バイアス応答をもたらす免疫ナノ治療薬(Immunonanotherapeutics)
GB0907989D0 (en) * 2009-05-08 2009-06-24 Hybrid Systems Ltd Multivalent adjuvant display
CN107252482A (zh) 2009-05-27 2017-10-17 西莱克塔生物科技公司 具有不同释放速率的纳米载体加工组分
EP3058953A1 (en) 2009-07-07 2016-08-24 The Research Foundation Of State University Of New York Lipidic compositions for induction of immune tolerance
US8653155B2 (en) * 2009-08-13 2014-02-18 Boston Scientific Scimed, Inc. Polymers having lipophilic hydrocarbon and biodegradable polymeric segments
CA2771863A1 (en) 2009-08-26 2011-03-17 Selecta Biosciences, Inc. Compositions that induce t cell help
WO2011084513A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
WO2011085231A2 (en) 2010-01-08 2011-07-14 Selecta Biosciences, Inc. Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines
US20110229556A1 (en) 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid-coated polymer particles for immune stimulation
US20110272836A1 (en) 2010-04-12 2011-11-10 Selecta Biosciences, Inc. Eccentric vessels
US20110262491A1 (en) 2010-04-12 2011-10-27 Selecta Biosciences, Inc. Emulsions and methods of making nanocarriers
WO2011150258A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
AU2011291522A1 (en) 2010-08-20 2013-01-24 Selecta Biosciences, Inc. Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza A virus M2E
WO2012027365A2 (en) 2010-08-23 2012-03-01 Selecta Biosciences, Inc. Targeted multi-epitope dosage forms for induction of an immune response to antigens
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
WO2012092552A1 (en) 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
BR112013024655A2 (pt) 2011-03-25 2016-12-20 Selecta Biosciences Inc nanotransportadores sintéticos para liberação mediada de modo osmótico
US9987354B2 (en) 2011-04-29 2018-06-05 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells
US20130028857A1 (en) 2011-07-29 2013-01-31 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
WO2013036302A1 (en) 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Induced tolerogenic dendritic cells for generating cd8+ regulatory t cells
CN110251675A (zh) 2013-05-03 2019-09-20 西莱克塔生物科技公司 降低或预防响应于非变应原性抗原的过敏反应的致耐受性合成纳米载体
JP7126806B2 (ja) 2013-06-04 2022-08-29 セレクタ バイオサイエンシーズ インコーポレーテッド 非免疫抑制性の抗原特異的免疫治療薬の反復投与
US20150359865A1 (en) 2014-06-17 2015-12-17 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease
US20160220501A1 (en) 2015-02-03 2016-08-04 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
US20150374815A1 (en) 2014-06-25 2015-12-31 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
WO2016037161A2 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
KR102656139B1 (ko) 2014-11-05 2024-04-11 셀렉타 바이오사이언시즈, 인크. 라팔로그를 포함하는 합성 나노담체 제조에서의 저hlb 계면활성제의 사용과 관련된 방법 및 조성물
IL318183A (en) 2016-03-11 2025-03-01 Selecta Biosciences Inc Formulations and doses of pegylated uricase
WO2018039465A1 (en) 2016-08-25 2018-03-01 Selecta Biosciences, Inc. Polyester polymer matrices for the delivery of allergens
EP3518956A1 (en) 2016-09-27 2019-08-07 Selecta Biosciences, Inc. Recombinant immunotoxins for use in the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2014521687A5 (enExample)
Chen et al. Advances in the polymeric delivery of nucleic acid vaccines
Ren et al. Adjuvant physiochemistry and advanced nanotechnology for vaccine development
Vajdy et al. Mucosal adjuvants and delivery systems for protein‐, DNA‐and RNA‐based vaccines
Cui et al. Vaccine adjuvants: current status, research and development, licensing, and future opportunities
Azmi et al. Recent progress in adjuvant discovery for peptide-based subunit vaccines
O’Hagan et al. Microparticles as vaccine adjuvants and delivery systems
Foged Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems
Reed et al. New horizons in adjuvants for vaccine development
Shah et al. Overview of vaccine adjuvants: introduction, history, and current status
Sahdev et al. Biomaterials for Nanoparticle Vaccine Delivery Systems: Sahdev, Ochyl and Moon
Lahiri et al. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond
Salvador et al. An overview on the field of micro‐and nanotechnologies for synthetic peptide‐based vaccines
Bachmann et al. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Arca et al. Chitosan-based systems for the delivery of vaccine antigens
Bal et al. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations
Goetz et al. Vaccine adjuvants for infectious disease in the clinic
Dey et al. Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens
JP2013530157A5 (enExample)
Akache et al. Adjuvants: engineering protective immune responses in human and veterinary vaccines
Beg et al. Colloidal drug delivery systems in vaccine delivery
Saupe et al. Immunostimulatory colloidal delivery systems for cancer vaccines
O’Hagan New generation vaccine adjuvants
WO2018183661A1 (en) Formulation for protection through controlled release of microparticles containing recombinant outer membrane vesicles
Ott et al. Development of vaccine adjuvants: a historical perspective